William Blair analyst Matt Phipps initiated coverage of Climb Bio (CLYM) with an Outperform rating and no price target The firm cites the potential of the company’s CD19 antibody, budoprutug, which is being developed across a range of autoimmune indications, for the rating. The simplicity of a monoclonal antibody will be attractive for community physicians who treat most autoimmune patients, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLYM: